The American Journal of Transplantation publishes results from Hansa Medical's first Phase II study with IdeS
Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that clinical results from Hansa Medical’s first Phase II study (ClinicalTrials.gov Identifier: NCT02224820) with lead candidate IdeS (INN: Imlifidase) will be published today by the American Journal of Transplantation (AJT), the monthly peer reviewed medical journal published by the American Society of Transplant Surgeons and the American Society of Transplantation."The publication in the AJT describes the design and results from our very first clinical study in